(cis)-4-((4-bromophenyl)sulfonyl)-2,6-dimethylmorpholine | 1374986-84-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (cis)-4-((4-bromophenyl)sulfonyl)-2,6-dimethylmorpholine
• 英文别名: (2S,6R)-4-(4-bromophenyl)sulfonyl-2,6-dimethylmorpholine
• CAS: 1374986-84-1
• 化学式: C₁₂H₁₆BrNO₃S
• 分子量: 334.234
• InChiKey: PXJLWKQTPUITTL-AOOOYVTPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (cis)-4-((4-bromophenyl)sulfonyl)-2,6-dimethylmorpholine 在 吡啶 、 氯化亚砜 、 2,2,6,6-四甲基-3,5-庚二酮 、 caesium carbonate 、 N,N-二甲基甲酰胺 、 copper(I) bromide 、 lithium hydroxide 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 3-(4-(((2S,6R)-2,6-dimethylmorpholino)sulfonyl)phenoxy)-N-(5-fluorothiazol-2-yl)-5-((3-methylbut-2-en-1-yl)oxy)benzamide
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators

  摘要：

  A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.03.008
• 作为产物：
  描述：

  4-溴苯磺酰氯 、 cis-2,6-dimethylmorpholine 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 (cis)-4-((4-bromophenyl)sulfonyl)-2,6-dimethylmorpholine
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators

  摘要：

  A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.03.008

文献信息

• [EN] ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYANOÉTHYLPYRAZOLO PYRIDONES ACYCLIQUES EN TANT QU'INHIBITEURS DE JANUS KINASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014146493A1

  公开（公告）日：2014-09-25

  The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

  这项即时发明提供了化合物I的公式，这些化合物是JAK抑制剂，因此对于治疗JAK介导的疾病如类风湿关节炎、哮喘、慢性阻塞性肺病和癌症是有用的。
• N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
  申请人：DINSMORE Christopher

  公开号：US20160272633A1

  公开（公告）日：2016-09-22

  Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.

  提供了一些I式化合物，它们是JAK抑制剂，并可用于治疗JAK介导的疾病。
• ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
  申请人：DINSMORE Christopher

  公开号：US20160272634A1

  公开（公告）日：2016-09-22

  The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

  本发明提供了式I的化合物，它们是JAK抑制剂，因此可用于治疗JAK介导的疾病，如类风湿性关节炎、哮喘、COPD和癌症。
• Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10059705B2

  公开（公告）日：2018-08-28

  The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

  本发明提供的式 I 化合物是 JAK 抑制剂，因此可用于治疗 JAK 介导的疾病，如类风湿性关节炎、哮喘、慢性阻塞性肺病和癌症。
• N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2976338B1

  公开（公告）日：2018-01-03